GlassScriptPhysician profile
Narendra L Nigalye
NPI 1659369056
$1,489.04
in general payments reported to CMS, 2019-2025
29 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $128 · 2021: $239 · 2022: $351 · 2023: $227 · 2024: $272 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.59 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $116.85 | 2021-2024 | |
| Novo Nordisk INC | $116.43 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $98.20 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $80.92 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $80.30 | 2021-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $78.48 | 2021-2024 | |
| Collaborative Care Diagnostics, LLC | $64.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.87 | 2021-2024 | Jardiance |
| Mylan Specialty L.P. | $49.61 | 2023-2024 | Yupelri |
| Abbvie INC. | $49.02 | 2021-2022 | |
| Radius Health, INC. | $46.23 | 2023-2024 | Tymlos |
| Medtronic Vascular, INC. | $43.50 | 2019 | |
| Exact Sciences Corporation | $34.32 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.82 | 2025 | Shingrix |
| Abbott Laboratories | $19.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.57 | 2020 | |
| Amgen INC. | $18.39 | 2025 | Prolia, Evenity |
| Horizon Therapeutics Plc | $18.30 | 2022 | |
| Recordati_rare_diseases_inc. | $18.29 | 2025 | Panhematin |
| Biogen, INC. | $17.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.06 | 2022 | |
| Sumitomo Pharma America, INC. | $16.30 | 2024 | Gemtesa |
| Allergan, INC. | $16.00 | 2019 | |
| Eisai INC. | $15.40 | 2020 | |
| Alkermes, INC. | $14.04 | 2021 | |
| Corium, LLC | $13.99 | 2021 | |
| Antares Pharma, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Nigalye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.